Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.
about
Emerging drugs for Guillain-Barré syndromeFisher syndrome: clinical features, immunopathogenesis and managementGuillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosisGuillain-Barré syndrome and variantsIVIG treatment and prognosis in Guillain-Barré syndromePharmacological treatment for pain in Guillain-Barré syndromeIntravenous immunoglobulin for Guillain-Barré syndromePharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndromeCorticosteroids for Guillain-Barré syndromeIntravenous immunoglobulin for Guillain-Barré syndromePharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndromeCorticosteroids for Guillain-Barré syndromeTreatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disordersCorticosteroids for Guillain-Barré syndromeProminent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain-Barré syndrome.Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europeDiagnosis of Guillain-Barré syndrome in children and validation of the Brighton criteriaClinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.Pathogenesis and treatment of immune-mediated neuropathies.Early recognition of poor prognosis in Guillain-Barre syndromeAntibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome.Treatment guidelines for Guillain-Barré Syndrome.Modifying the Medical Research Council grading system through Rasch analyses.Action mechanism of corticosteroids to aggravate Guillain-Barré syndrome.Treatment of Guillain-Barré syndrome and CIDP.Clinical uses of intravenous immunoglobulin.Immunotherapy in Peripheral NeuropathiesGuillain-Barré syndrome and its treatment.Short-Term Prognosis of Mechanically Ventilated Patients With Guillain-Barré Syndrome Is Worsened by Corticosteroids as an Add-On Therapy.Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update.The Importance of Rare Subtypes in Diagnosis and Treatment of Peripheral Neuropathy: A Review.Determination of pain and response to methylprednisolone in Guillain-Barré syndrome.Guillain-Barré syndrome: update on immunobiology and treatment.Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatmentAutoantibodies in neuromuscular autoimmune disorders.The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action.New strategies in the management of Guillain-Barré syndrome.Immune Gamma Globulin Therapeutic Indications in Immune Deficiency and Autoimmunity.Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment.Proximal nerve lesions in early Guillain-Barré syndrome: implications for pathogenesis and disease classification.
P2860
Q22241376-A4C17793-9A5E-43FA-B62A-E169E27755B7Q22241475-2CE501C8-93B8-43A3-B717-053A8255CBB9Q22251013-B3FCDB82-6675-43C4-A833-5CF7441DA606Q22252353-D380B056-791A-4979-809F-C28C4B88A169Q22252627-0FD76DBC-9051-494A-AC14-B61EBDBE2DE6Q24186580-E3C092AE-A022-4AFE-97C2-1EF92602F9CCQ24193522-3D388A8F-881D-462F-A77F-367BB9B479DCQ24200916-6580B007-D9F5-4A34-B047-2C217B20E349Q24201413-E677E9B3-D5D2-4F84-AAFB-1F907B16B35FQ24202100-FBC846D2-2E8C-45B3-805C-E20F5D1F7699Q24235600-0736B02E-56A6-41B8-9540-8005A876EA84Q24240016-9912DC19-FF66-4872-8B09-D19CB5DCB8D4Q24246272-7D7EC031-8762-4D25-9412-C639ABE55ACEQ24246424-6173584E-EDA6-44C7-BCEB-607CB664D158Q33332176-231D56B0-534A-4EFA-9081-370D908FCDA4Q33419638-0F2AAA5F-80AB-4098-ADC4-5E58B1A11D47Q33627830-7F4228B4-11EE-47C3-9A6E-47BC7E7F4502Q34072287-8139A0D4-01E8-4285-BA00-80C873C5D3AEQ34409385-498CBDF0-1C03-4F73-8EFD-713B46758851Q34686090-581E222F-0F9F-4D42-A568-CADC098AED12Q35072720-E538647A-B922-4025-9CA1-33CFC960F29AQ35152989-BE75D2F0-71AC-4F93-B104-33D9F9116D26Q35918784-F0473405-E0F7-4120-A1D6-58B1C77C5459Q36045649-F1551B6C-251A-43FF-A474-7BB93F425F42Q36164126-F23E909D-136E-4FDA-AD94-76B26A2E9CA8Q36264883-68D218D7-BB6C-4538-A829-A567B87027E2Q36484418-5DB705F0-494F-467E-AD20-8431F4C2A4E8Q36641540-AC3864F6-6F81-4FCA-9613-F5129F668009Q37176350-2FFCE961-11B9-4EFF-82BB-9721C80250DCQ37329516-557631CB-0E04-4846-8CCD-3EAE6CF138E3Q37381546-44D92763-ECCC-414E-9EC7-D5A9C75E45D7Q37424369-BF678100-0E89-4E6A-8F18-3D5796D7AAF0Q37600859-215EF163-EFB0-419D-9A70-47C311F154F1Q37696931-9709FC29-5F5B-4BFA-B935-53123C24F21CQ37754738-11E8CE02-F17F-433C-9789-1235206021ABQ37862736-93AD229E-41E5-46D2-A90A-9419D2D5EDEAQ38140727-6EE6A349-1488-4BAF-B08D-C7479D6344EAQ38842992-01CAB0D4-CFD7-4B23-9A58-B827F5DEE703Q38862736-61B6EBC9-56A3-4CA6-8A88-3B4E1AF7C086Q38868347-2A19FACE-F5F0-4E12-9035-29D4D1BDF628
P2860
Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Effect of methylprednisolone w ...... ré syndrome: randomised trial.
@en
Effect of methylprednisolone w ...... ré syndrome: randomised trial.
@nl
type
label
Effect of methylprednisolone w ...... ré syndrome: randomised trial.
@en
Effect of methylprednisolone w ...... ré syndrome: randomised trial.
@nl
prefLabel
Effect of methylprednisolone w ...... ré syndrome: randomised trial.
@en
Effect of methylprednisolone w ...... ré syndrome: randomised trial.
@nl
P2093
P1433
P1476
Effect of methylprednisolone w ...... ré syndrome: randomised trial.
@en
P2093
Dutch GBS study group
F G Avander Meché
J Meulstee
L H Visser
P A van Doorn
P I M Schmitz
R van Koningsveld
P304
P356
10.1016/S0140-6736(03)15324-X
P407
P577
2004-01-01T00:00:00Z